ACCUPRIL (quinapril hydrochloride) by R-Pharm US is clinical pharmacology mechanism of action quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ace activity in human subjects and animals. Approved for hypertension, to lower blood pressure, the management of heart failure and 3 more indications. First approved in 1991.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ACCUPRIL (quinapril hydrochloride) is an oral ACE inhibitor that blocks angiotensin-converting enzyme to reduce angiotensin II formation, lowering blood pressure and reducing cardiac workload. It is indicated for hypertension and congestive heart failure management. The drug works by inhibiting circulating and tissue ACE activity, thereby reducing vasoconstriction and aldosterone secretion.
Product approaching loss of exclusivity with moderate competitive pressure (30 points); brand team likely focused on market defense and transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Mechanism of Action Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The…
Worked on ACCUPRIL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Management With Accupril Post Bypass Graft
Working on ACCUPRIL in a LOE-approaching environment offers limited growth opportunity; roles focus on defending market share against generics and combination competitors rather than brand building. Career mobility may be limited unless assigned to transition projects or parallel product lines within the R-Pharm US cardiovascular portfolio.